The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated substantial returns, the end of its patent opened the avenue to generic versions, dramatically diminishing revenue. This presents a particular risk for pharmaceutical companies depending on similar blockbuster medicatio

The history of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a flood of lower-priced alternatives , significantly eroding its position . While specific firms may try to capitalize on similar conditions , the present landsc